CA3185604A1 - Inhibitors of apol1 and use of the same - Google Patents
Inhibitors of apol1 and use of the sameInfo
- Publication number
- CA3185604A1 CA3185604A1 CA3185604A CA3185604A CA3185604A1 CA 3185604 A1 CA3185604 A1 CA 3185604A1 CA 3185604 A CA3185604 A CA 3185604A CA 3185604 A CA3185604 A CA 3185604A CA 3185604 A1 CA3185604 A1 CA 3185604A1
- Authority
- CA
- Canada
- Prior art keywords
- linear
- groups
- branched
- optionally substituted
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063038275P | 2020-06-12 | 2020-06-12 | |
| US63/038,275 | 2020-06-12 | ||
| US202063040183P | 2020-06-17 | 2020-06-17 | |
| US63/040,183 | 2020-06-17 | ||
| PCT/US2021/036954 WO2021252859A1 (en) | 2020-06-12 | 2021-06-11 | Inhibitors of apol1 and use of the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3185604A1 true CA3185604A1 (en) | 2021-12-16 |
Family
ID=76731125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3185604A Pending CA3185604A1 (en) | 2020-06-12 | 2021-06-11 | Inhibitors of apol1 and use of the same |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12281102B2 (https=) |
| EP (1) | EP4165022A1 (https=) |
| JP (1) | JP2023530271A (https=) |
| CN (1) | CN116157393A (https=) |
| AU (1) | AU2021286728A1 (https=) |
| CA (1) | CA3185604A1 (https=) |
| WO (1) | WO2021252859A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618746B2 (en) | 2018-12-17 | 2023-04-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| WO2021154997A1 (en) | 2020-01-29 | 2021-08-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| IL296035A (en) | 2020-03-06 | 2022-10-01 | Vertex Pharma | Methods of treating apol-1 dependent focal segmental glomerulosclerosis |
| CN115867543A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| CA3185604A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
| CN116547287B (zh) | 2020-08-26 | 2025-09-26 | 弗特克斯药品有限公司 | Apol1的抑制剂及其使用方法 |
| US12612379B2 (en) | 2021-11-30 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| MX2024008868A (es) * | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1266763B (de) * | 1965-07-27 | 1968-04-25 | Kalle Ag | Verfahren zur Herstellung von in 3-Stellung substituierten Indol- und Indazolderivaten |
| EP0924209B1 (en) | 1997-12-19 | 2003-05-02 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
| GB9816263D0 (en) * | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
| GB9905010D0 (en) | 1999-03-04 | 1999-04-28 | Merck Sharp & Dohme | Therapeutic agents |
| AU7514700A (en) | 1999-09-07 | 2001-04-10 | Syngenta Participations Ag | Cyanopiperidines |
| FR2801585B1 (fr) | 1999-11-25 | 2002-02-15 | Fournier Ind & Sante | Nouveaux antagonistes des recepteurs de l'ii-8 |
| GB0003397D0 (en) | 2000-02-14 | 2000-04-05 | Merck Sharp & Dohme | Therapeutic agents |
| AU2002211828A1 (en) | 2000-10-02 | 2002-04-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| FR2824826B1 (fr) | 2001-05-17 | 2003-11-07 | Fournier Lab Sa | Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8 |
| FR2824827B1 (fr) | 2001-05-17 | 2004-02-13 | Fournier Lab Sa | Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8 |
| ES2234451T1 (es) | 2001-11-14 | 2005-07-01 | Teva Pharmaceutical Industries Ltd. | Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion. |
| WO2003104180A1 (en) | 2002-06-05 | 2003-12-18 | Natco Pharma Limited | Process for the preparation of 4-(4-fluorobenzoyl) butyric acid |
| WO2004058717A1 (en) | 2002-12-20 | 2004-07-15 | X-Ceptor Therapeutics, Inc. | Isoquinolinone derivatives and their use as therapeutic agents |
| JP2007504221A (ja) | 2003-09-03 | 2007-03-01 | ガラパゴス・エヌブイ | 新規な４−ピペリジンカルボキシアミドおよび５ｈｔ２ａ受容体関連障害に対する薬剤の製造のためのその使用 |
| BRPI0507657A (pt) | 2004-03-03 | 2007-07-10 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo |
| WO2007061763A2 (en) | 2005-11-22 | 2007-05-31 | Merck & Co., Inc. | Indole orexin receptor antagonists |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| DK2178870T3 (en) | 2007-08-17 | 2018-10-22 | Lg Chemical Ltd | INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE |
| JP2011525915A (ja) * | 2008-06-26 | 2011-09-29 | アムジエン・インコーポレーテツド | キナーゼ阻害薬としてのアルキニルアルコール類 |
| CN105254557A (zh) | 2009-05-29 | 2016-01-20 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
| WO2012025155A1 (en) | 2010-08-26 | 2012-03-01 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases |
| US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| EP3049405A4 (en) | 2013-09-26 | 2017-03-08 | Pharmakea Inc. | Autotaxin inhibitor compounds |
| EP3461812B1 (en) | 2014-03-27 | 2021-10-13 | Academisch Medisch Centrum | N-(5-(biphen-4-ylmethyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase |
| EP3186225A4 (en) | 2014-08-27 | 2018-02-28 | The Governing Council of the University of Toronto | Cannabinoid type 1 receptor modulators |
| US10654838B2 (en) | 2014-10-08 | 2020-05-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Aminopyridine compounds useful as inhibitors of protein prenylation |
| HUE053705T2 (hu) | 2015-08-27 | 2021-07-28 | Pfizer | Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként |
| CN106008477B (zh) * | 2016-06-02 | 2019-02-26 | 苏州大学 | 3-(2-芳基-1h-吲哚-3-基)-4-羟基呋喃-2(5h)-酮及其合成方法 |
| EP3787669A4 (en) | 2018-04-30 | 2022-03-30 | The Trustees of Indiana University | COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES |
| IL278785B2 (en) | 2018-05-22 | 2025-03-01 | Ionis Pharmaceuticals Inc | Modulators of apol1 expression |
| US11618746B2 (en) * | 2018-12-17 | 2023-04-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| WO2021154997A1 (en) | 2020-01-29 | 2021-08-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| US20210246121A1 (en) | 2020-02-04 | 2021-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and methods of using same |
| IL296035A (en) | 2020-03-06 | 2022-10-01 | Vertex Pharma | Methods of treating apol-1 dependent focal segmental glomerulosclerosis |
| JP2023524563A (ja) | 2020-05-07 | 2023-06-12 | ラムバム メド－テック リミテッド | Ａｐｏｌ１－関連疾患の治療に使用するための組成物 |
| CA3185604A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
| CN115867543A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| CN115867532A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1的抑制剂及其用途 |
| CN116547287B (zh) | 2020-08-26 | 2025-09-26 | 弗特克斯药品有限公司 | Apol1的抑制剂及其使用方法 |
| US20230119114A1 (en) | 2021-08-26 | 2023-04-20 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitors and methods of using same |
| EP4440697A1 (en) | 2021-11-30 | 2024-10-09 | Vertex Pharmaceuticals Incorporated | Spirocyclic inhibitors of apol1 and methods of using same |
| US12612379B2 (en) | 2021-11-30 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| CN119212986A (zh) | 2022-02-08 | 2024-12-27 | 弗特克斯药品有限公司 | 作为apol1的抑制剂的螺哌啶衍生物及其使用方法 |
| CA3251050A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE |
| AU2023219516A1 (en) | 2022-02-08 | 2024-08-22 | Vertex Pharmaceuticals Incorporated | 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same |
| EP4476228A1 (en) | 2022-02-08 | 2024-12-18 | Vertex Pharmaceuticals Incorporated | 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same |
-
2021
- 2021-06-11 CA CA3185604A patent/CA3185604A1/en active Pending
- 2021-06-11 AU AU2021286728A patent/AU2021286728A1/en not_active Abandoned
- 2021-06-11 JP JP2022575989A patent/JP2023530271A/ja active Pending
- 2021-06-11 US US17/345,268 patent/US12281102B2/en active Active
- 2021-06-11 EP EP21736922.2A patent/EP4165022A1/en not_active Withdrawn
- 2021-06-11 WO PCT/US2021/036954 patent/WO2021252859A1/en not_active Ceased
- 2021-06-11 CN CN202180056005.4A patent/CN116157393A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021286728A1 (en) | 2023-01-19 |
| WO2021252859A1 (en) | 2021-12-16 |
| JP2023530271A (ja) | 2023-07-14 |
| US20230011118A1 (en) | 2023-01-12 |
| CN116157393A (zh) | 2023-05-23 |
| US12281102B2 (en) | 2025-04-22 |
| EP4165022A1 (en) | 2023-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3185604A1 (en) | Inhibitors of apol1 and use of the same | |
| US12116343B2 (en) | Inhibitors of APOL1 and methods of using same | |
| US20250042878A1 (en) | Inhibitors of apol1 and methods of using same | |
| CA3185144A1 (en) | Inhibitors of apol1 and use of the same | |
| WO2018196677A1 (zh) | 氟代烯丙胺衍生物及其用途 | |
| CA3049912A1 (en) | Modulators of estrogen receptor proteolysis and associated methods of use | |
| IL129243A (en) | Vitronectin receptor antagonists, a process for their preparation, pharmaceutical preparations containing them and their use in the preparation of drugs in the treatment of bone thinning and prevention of vascular formation | |
| AU2013331626A1 (en) | Therapeutic compounds and compositions | |
| US20250084094A1 (en) | Spirocyclic inhibitors of apol1 and methods of using same | |
| WO2023154310A1 (en) | 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same | |
| WO2022148317A1 (zh) | 2-氨基嘧啶类化合物及其药物组合物和应用 | |
| CA3206847A1 (en) | Modulators of fpr1 and methods of using the same | |
| AU2019339703B2 (en) | Immunomodulators, compositions and methods there of | |
| JP4685307B2 (ja) | ビトロネクチン受容体アンタゴニスト | |
| HK40049451A (en) | Immunomodulator, composition and preparation method thereof | |
| NZ614321B2 (en) | Glycine transporter-inhibiting substances |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241112 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251128 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260128 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260204 |